Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 24

1.

Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial.

Margolis KL, O'Connor PJ, Morgan TM, Buse JB, Cohen RM, Cushman WC, Cutler JA, Evans GW, Gerstein HC, Grimm RH Jr, Lipkin EW, Narayan KM, Riddle MC Jr, Sood A, Goff DC Jr.

Diabetes Care. 2014 Jun;37(6):1721-8. doi: 10.2337/dc13-2334. Epub 2014 Mar 4.

PMID:
24595629
2.

The work-up for mixed hyperlipidemia: a case study.

Rehman HU.

J Fam Pract. 2012 Mar;61(3):133-6.

PMID:
22393551
3.

One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.

Ferdinand KC, Davidson MH, Kelly MT, Setze CM.

Am J Cardiovasc Drugs. 2012 Apr 1;12(2):117-25. doi: 10.2165/11597940-000000000-00000.

PMID:
22263674
4.

Use of fibrates in the United States and Canada.

Jackevicius CA, Tu JV, Ross JS, Ko DT, Carreon D, Krumholz HM.

JAMA. 2011 Mar 23;305(12):1217-24. doi: 10.1001/jama.2011.353.

5.

Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.

Jones PH, Cusi K, Davidson MH, Kelly MT, Setze CM, Thakker K, Sleep DJ, Stolzenbach JC.

Am J Cardiovasc Drugs. 2010;10(2):73-84. doi: 10.2165/10061630-000000000-00000.

PMID:
20136164
6.
7.

Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study.

Jones PH, Davidson MH, Kashyap ML, Kelly MT, Buttler SM, Setze CM, Sleep DJ, Stolzenbach JC.

Atherosclerosis. 2009 May;204(1):208-15. doi: 10.1016/j.atherosclerosis.2008.09.027. Epub 2008 Oct 5.

PMID:
18996523
8.

Comparison of treatment of severe high-density lipoprotein cholesterol deficiency in men with daily atorvastatin (20 mg) versus fenofibrate (200 mg) versus extended-release niacin (2 g).

Alrasadi K, Awan Z, Alwaili K, Ruel I, Hafiane A, Krimbou L, Genest J.

Am J Cardiol. 2008 Nov 15;102(10):1341-7. doi: 10.1016/j.amjcard.2008.07.010. Epub 2008 Sep 11.

PMID:
18993152
9.

Statins but not fibrates improve the atherogenic to anti-atherogenic lipoprotein particle ratio: a randomized crossover study.

Chan SY, Mancini GB, Ignaszewski A, Frohlich J.

BMC Clin Pharmacol. 2008 Oct 28;8:10. doi: 10.1186/1472-6904-8-10.

10.

Plasma PCSK9 levels are significantly modified by statins and fibrates in humans.

Mayne J, Dewpura T, Raymond A, Cousins M, Chaplin A, Lahey KA, Lahaye SA, Mbikay M, Ooi TC, Chrétien M.

Lipids Health Dis. 2008 Jun 11;7:22. doi: 10.1186/1476-511X-7-22.

11.

Differential effect of atorvastatin and fenofibrate on plasma oxidized low-density lipoprotein, inflammation markers, and cell adhesion molecules in patients with type 2 diabetes mellitus.

Hogue JC, Lamarche B, Tremblay AJ, Bergeron J, Gagné C, Couture P.

Metabolism. 2008 Mar;57(3):380-6. doi: 10.1016/j.metabol.2007.10.014.

PMID:
18249211
12.

Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia.

Hogue JC, Lamarche B, Deshaies Y, Tremblay AJ, Bergeron J, Gagné C, Couture P.

Metabolism. 2008 Feb;57(2):246-54. doi: 10.1016/j.metabol.2007.09.008.

PMID:
18191056
13.

Effects of simvastatin on the development of the atrial fibrillation substrate in dogs with congestive heart failure.

Shiroshita-Takeshita A, Brundel BJ, Burstein B, Leung TK, Mitamura H, Ogawa S, Nattel S.

Cardiovasc Res. 2007 Apr 1;74(1):75-84. Epub 2007 Jan 11.

14.
17.

A 16-week fenofibrate treatment increases LDL particle size in type IIA dyslipidemic patients.

Lemieux I, Laperrière L, Dzavik V, Tremblay G, Bourgeois J, Després JP.

Atherosclerosis. 2002 Jun;162(2):363-71.

PMID:
11996956
18.

Pancreatitis associated with simvastatin plus fenofibrate.

McDonald KB, Garber BG, Perreault MM.

Ann Pharmacother. 2002 Feb;36(2):275-9.

PMID:
11847949
19.

Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia.

Ellen RL, McPherson R.

Am J Cardiol. 1998 Feb 26;81(4A):60B-65B. Review.

PMID:
9526816
20.

Clinical pharmacokinetics of fibric acid derivatives (fibrates).

Miller DB, Spence JD.

Clin Pharmacokinet. 1998 Feb;34(2):155-62. Review.

PMID:
9515185
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk